Asthma and Multimorbidity Amongst Ethnic Minority Groups in High Income Countries Authors: Mamidipudi Thirumala Krishna, Saibal Moitra, Anna Freeman, Ben Ainsworth, Rebecca Knibb, Ramesh Kurukulaaratchy, Adel H. Mansur Published: 2026 ABSTRACT ABSTRACTAsthma is one of the commonest noncommunicable diseases worldwide. Poor clinical outcomes have been reported in asthma amongst ethnic minority groups (EMGs) and reasons are likely to be multifactorial. There is a suggestion that underlying disease may behave differently amongst EMGs, alongside other factors including deprivation, cultural, religious, social, literacy, patient beliefs, healthcare access, treatment adherence, alongside greater burden of multimorbidity. Multimorbidity (presence of ≥ 2 long‐term health conditions) in asthma is increasingly known to contribute to greater asthma burden, with differences in multimorbidity burden and patterns seen across ethnicities with a tight association with deprivation. Earlier onset of multimorbidity with relatively reduced survival has been reported amongst EMG patients, particularly those from a deprived background compared to White patients. Data regarding asthma, multimorbidity and ethnicity are scant, but emerging data suggest that multimorbidity is heterogenous, and that ethnic background is associated with variations in asthma outcomes and multimorbidity phenotypes. What is currently lacking is population‐based research with a joined‐up interrogation of primary care and secondary care databases to determine the prevalence and patterns of T2 and non T2 multimorbidity in asthma amongst EMGs, and analysis of patterns of associations and link to socio‐demographic variables and clinical outcomes. Deeper insight into views of EMG patients and their carers regarding lived experiences of asthma and multimorbidity management, as well as those of healthcare professionals is needed, to allow development of culturally tailored resources. These studies are likely to shape a holistic culturally tailored multidimensional and an equitable approach to management of asthma with multimorbidity amongst EMGs. Ethnicity‐Based Disparities in Asthma in High Income Countries Asthma is a chronic inflammatory disorder affecting lower airways and is characterised by mucosal inflammation and bronchial hyperreactivity. It is one of the most common noncommunicable diseases affecting over 350 million people worldwide [1]. A previous report in 2018 estimated 65,000 asthma‐related admissions in England annually with a positive correlation (r = 0.67) with index of multiple deprivation [2]. Recent data (2022–23) from the UK asthma hospitalisation dashboard reported 92,209 hospitalisations (125.5/100,000) [3]. There is heterogeneity in the nomenclature used to describe ethnicity in High Income Countries. The UK Office of National Statistics 2021 census lists four main categories of ethnicity including Asian (Indian, Pakistani, Bangladeshi and Chinese), Black (African, Caribbean and other Black), White and Mixed or other ethnic groups. In this article ethnic minority groups (EMGs) refers to South Asian and Afro‐Caribbean/Black population. People living in deprived areas are more likely to suffer from acute asthma, and a high proportion of people from EMGs are socioeconomically deprived [4, 5, 6]. The English indices of deprivation 2019 data suggest that 19.3% of Bangladeshi, 31.1% Pakistani and 15.2% of Black people live in 10% of most deprived neighbourhoods [7]. Approximately 13% (8.17 m) of the UK population are from EMGs, and 1 in 5 people in major cities such as London and Birmingham are of South Asian origin. In a longitudinal cohort study involving UK primary care database, Subramanian et al. reported that the prevalence of allergic rhinitis and asthma amongst the British White population was 11.5% and 7.2% respectively [8]. The prevalence in British South Asian, British Afro‐Caribbean and British Mixed Ethnic groups was 7%, 6% and 5.6% for allergic rhinitis and 7.5%, 7% and 5.7% for asthma respectively [8]. This study showed that the incident risk of allergic rhinitis, asthma, atopic dermatitis and ten organ‐specific and systemic autoimmune conditions were significantly greater amongst British South Asian and British Afro Caribbean people compared to British White people [8]. In the Bradford born cohort involving children of White (N = 495), Pakistani (N = 961) and other ethnicities (N = 190), the prevalence of doctor ‘ever diagnosed asthma’ was 8.9%, 13.4% and 3.2% respectively [9]. In a systematic review and meta‐analysis of 13 prevalence studies (published from 1981 to 2002) in British children, Netuveli et al. reported ethnicity‐based variations [10]. The pooled prevalence (95% CI) of clinician‐diagnosed asthma was 10.6% (4.6%–16.7%), 15.0% (3.5%–26.5%), 7.6% (3.7%–11.4%) in White, Black and South Asians respectively, and the risk (odds ratio 2‐fold higher) of asthma admission was higher amongst Black and South Asian children compared to White ethnicity [10]. The prevalence of asthma is significantly higher amongst Black and Puerto Rican population in USA and similar observations have been reported from Australia [11, 12]. Ethnicity‐based disparities have attracted great attention in High Income Countries including the UK, USA and Australia in view of poor clinical outcomes in asthma, allergic rhinitis, and food allergy [13, 14, 15]. Poor clinical outcomes have been linked to multiple factors including cultural, social, religious, lower literacy, socioeconomic status, deprived area of residence and co‐existing multiple long‐term conditions [6, 13]. Most evidence comes from retrospective observational studies involving large database searches interrogating data from primary and secondary care and few involving prospective surveys, both in paediatric and adult populations. Ethnicity‐based disparities in aero‐allergen sensitisation have been reported amongst EMGs in High Income Countries. For example, the risk of cockroach sensitisation is 16‐fold higher in African American children and has been linked to rural area of residence (4‐fold higher) and deprivation (12‐fold higher) [16]. In a study involving difficult‐to‐control asthma in central England, Mansur et al. showed that the risk of house dust mite sensitisation is significantly greater amongst British EMGs, most of whom were from South Asian ethnicity [17]. Higher titres of serum specific IgE to dust mite and higher levels of blood eosinophils were detected compared to Caucasian White patients [17]. A number of poor clinical outcomes have been reported amongst people with asthma from EMGs in the UK, USA and Australia [6, 13, 15]. EMG patients have poorer asthma control as evidenced by more frequent visits to the emergency room, greater oral corticosteroid usage, intensive care admissions and higher rates of fatal asthma [13, 15, 18]. Multiple factors may impact these outcomes, including poor treatment adherence and/or engagement with health services and access, more social deprivation associated with EMGs which causes poor quality of life, and/or whether the disease is inherently more severe and complex amongst EMGs [19]. In a recent study in a specialist UK National Health Service Allergy service involving a relatively small cohort of British South Asian patients with food allergy, Osborne et al. reported significantly more frequent allergic reactions alongside poorer asthma and eczema control compared to the Caucasian White population [20]. Furthermore, a higher standardised incident risk of anaphylaxis has been reported amongst British and Australian EMG patients [12, 21]. It is well recognised that both severe anaphylaxis and fatal anaphylaxis are closely associated with poor asthma control [22, 23, 24]. A disproportionately high rate of fatal asthma and fatal anaphylaxis have been reported amongst Black patients and Puerto Rican patients in the USA [25, 26, 27, 28]. The main aim of this narrative review is to examine the published evidence relating to (a) intersectionality of asthma, multimorbidity and ethnicity, (b) the adverse impact of multimorbidity on clinical outcomes in asthma, (c) emerging evidence regarding the benefit of addressing common co‐existing long‐term conditions on clinical outcomes and (d) identifying research gaps relating to asthma and multimorbidity amongst EMGs. Contextualising Asthma and Multimorbidity Multimorbidity is defined as the presence of two or more long‐term conditions including physical and mental illnesses in the same patient at a given time [29]. Broadly, there are two types of long‐term co‐existing conditions in asthma (Figure 1), T1 (non‐allergic) and T2 (allergic), and these are discussed in the later sections. Asthma and associated co‐existing long‐term conditions. Illustration of interplay between asthma and multimorbidity (T2 and non T2). CAD, Coronary artery disease; COPD, Chronic obstructive pulmonary disease; NSAID, Nonsteroidal anti‐inflammatory drugs. The National Institute of Clinical and Care Excellence published guidelines on clinical assessment and management of multimorbidity given its adverse impact on health‐related quality of life, excess mortality, polypharmacy, enhanced risk of drug‐related adverse events, lesser compliance and higher unplanned use of clinical services, all contributing to excess healthcare costs [29]. Health services in secondary and tertiary care, and clinical guidelines relating to long‐term conditions including asthma are currently single condition‐focused resulting in patients receiving care from multiple specialists, and patients are at a potential risk of fragmented and disjointed care [29, 30]. For example, in the UK National Health Service, a patient with uncontrolled asthma, allergic rhinitis, food allergy, diabetes, obesity and hyperlipidaemia might be attending a specialist allergy, specialist asthma, specialist diabetes and specialist lipid/metabolic clinics, in addition to their primary care reviews. There are studies which show multimorbidity is more prevalent amongst men, though other studies show the prevalence to be more in women, amongst people from EMGs, those from deprived areas, smokers, obese patients and those with mental health problems [31, 32, 33, 34, 35, 36]. Data from the Global Burden of Disease Study, suggested that cancer, cardiovascular diseases, chronic respiratory diseases including asthma and chronic obstructive pulmonary disease and diabetes were the most common noncommunicable disease conditions linked to death in 2015 in England and in the global adult population [37, 38]. One study in 2020 reported that the overall prevalence of multimorbidity defined as ≥ 2 long‐term conditions was ~15% in England, and the prevalence rate was significantly influenced by age [31]. Asthma, autism and epilepsy dominated in children aged ≤ 19 years, depression and asthma in those 20–49 years, hypertension and depression for those between 50 and 59 years and cardiometabolic conditions and osteoarthritis in those ≥ 60 years [31]. It has also been reported that multimorbidity occurs in 35% and 55% of people between 55–64 years and 65–74 years respectively. Deprivation is one of the most important risk factors for multimorbidity, with a nearly 50% higher risk [39, 40, 41]. In a population‐based study involving England population between 2004 and 2015, the prevalence of basic multimorbidity (≥ 2 chronic conditions) and complex multimorbidity (≥ 3 or more conditions involving 3 body systems) increased from 30.8% and 15.1% to 52.8% and 32.7% respectively [42]. Deprivation was associated with increased incidence of complex multimorbidity with a median seven‐year younger age of onset [42]. Multimorbidity is therefore highly relevant in patients from EMGs, as a large majority are from a lower socio‐economic stratum living in deprived areas, have lesser literacy and this is further compounded by barriers to access elective healthcare and poor compliance with clinical management [4, 33, 43]. A population‐based study interrogating primary and secondary healthcare records in England from 2010 to 2020 involving ~2.5 M people with ≥ 2 long‐term conditions showed that early onset (< 40 years) multimorbidity was more common amongst South Asian (56%) and Black people (59%) compared to Caucasian White people (42%), and that South Asian and Black people died early with a lesser median survival of 9 and 13 years respectively, compared to Caucasian White people [44]. These observations highlight an urgent need for a more nuanced and novel targeted approach to the management of multimorbidity amongst EMGs, specifically focused on prevention, early diagnosis and provision of holistic care, preferably in accessible community settings. Recent studies have highlighted the importance of recognising the adverse impact of multimorbidity in both children and adults with asthma [6, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54]. T2‐related conditions include allergic rhinitis, atopic dermatitis, food allergy, nasal polyps, and chronic rhinosinusitis and often co‐exist in a significant proportion of patients alongside a number of non‐T2 conditions such as functional breathing disorders, mental illness, obesity, obstructive sleep apnoea, metabolic syndromes including diabetes and dyslipidaemia, cardiovascular disorders, chronic respiratory diseases such as bronchiectasis and chronic obstructive pulmonary disease, chronic pain conditions, osteoporosis, gastro‐oesophageal reflux, and autoimmune conditions (Figure 1). Whilst T2 co‐existing long‐term conditions might be predicted to be part of an atopic diathesis syndrome, the high prevalence of non‐T2 conditions shown by these studies demonstrates that a far wider spectrum of multimorbidity is clinically relevant in such patients. Some of these associations may plausibly reflect shared biological mechanisms not yet delineated or, alternatively, iatrogenic effects such as corticosteroid‐related disease impacts. These studies have shown that numerous individual co‐existing T2 and non‐T2 long‐term conditions as well as cumulative multimorbidity count are significant risk factors for poor asthma outcomes both amongst children and adults including worse exacerbations, lung function, asthma control, and oral corticosteroid dependency [45]. Of note, numerous co‐existing T2 and non‐T2 long‐term conditions were also identified as independent barriers to achieving severe asthma remission with biologic therapies in a recent systematic review and meta‐analysis [55]. The nature of multimorbidity in difficult‐to‐treat/severe asthma and how that is associated with patient outcomes is not well understood. Recently Kurukulaaratchy et al. [46] used data from the UK‐based Wessex AsThma CoHort of difficult asthma (WATCH) to model the association of multimorbidity with asthma severity‐risk in difficult‐to‐treat asthma. Following an iterative approach, they developed a Multimorbidity in Difficult Asthma Score (MiDAS) comprising the seven comorbidities in WATCH that retained significant association with a composite asthma severity measure. Those were rhinitis, gastro‐oesophageal reflux disease, breathing pattern disorder, obesity, bronchiectasis, non‐steroidal anti‐inflammatory drug‐exacerbated respiratory disease, and obstructive sleep apnoea. MiDAS was then tested amongst four international cohorts (USA, Singapore, and 2 in Australia) where it replicated well. Higher MiDAS correlated with poor clinical outcomes including worse quality of life, asthma control, psychological distress and biomarkers of inflammation including leptin, IL‐4, IL‐5 and CRP [46]. Both the WATCH, Australian and USA cohorts included in this study were overwhelmingly White Caucasian, though the US cohort included a substantial minority of Black Americans. Of note, the Singapore cohort showed the weakest replication of MiDAS and had no White patients but was predominantly Chinese or Malay. This emphasises a need to recognise that the nature of multimorbidity in asthma may vary for different ethnic groups. Nevertheless, MiDAS provides a tool for clinicians to start to recognise the presence and potential impact of multimorbidity in their patients with difficult‐to‐treat asthma. It could then act as a prompt to guide more holistic treatment options. As well as asthma and allergic conditions, there is a high risk of diabetes, metabolic disorders including obesity, hypertension, coronary artery disease, mental health and autoimmune conditions such as rheumatoid arthritis and lupus, amongst EMGs in High Income Countries [8, 56, 57, 58, 59, 60, 61]. Gibson‐Scipio et al. [62] investigated the impact of psychological distress and asthma‐related anxiety with asthma outcomes amongst urban African American young adults with poorly controlled asthma. Applying a multivariable model, they reported that higher somatisation scores and asthma‐related anxiety scores correlated negatively with asthma control and higher asthma attacks. Pate et al. analysed USA National Health Survey interview data 2021 involving 7343 children (age 2–17 years) and adults (≥ 18 years) and analysed the prevalence of ‘asthma only’ and those with asthma and allergy co‐existing long‐term conditions, as per symptoms involving skin, nose and eyes as a surrogate for hay fever, allergic rhinitis, food allergy and eczema [63]. Eight percent of the whole cohort had asthma, and over 50% reported T2 long‐term conditions [63]. The prevalence of asthma–T2 long‐term conditions was significantly higher amongst deprived patients as per federal poverty levels (< 100% vs. ≥ 200%) and non‐Hispanic Black (vs non‐Hispanic White) people [63]. Baptist et al. [5] investigated risk factors for asthma exacerbations amongst American patients with severe asthma in the CHRONICLE cohort (followed from 2018 to 2022). 180 Black and 570 non‐Black (Latino or non‐Hispanic) patients who were not receiving biologics were included in a propensity score analysis involving 7 domains—demographics, spirometry, air pollution exposure, co‐existing long‐term conditions (anxiety, atopic dermatitis or eczema, chronic obstructive pulmonary disease, depression, diabetes, gastroesophageal reflux disease, valvular heart disease, hypertension, and allergic rhinitis), smoking status, socioeconomic status and concurrent maintenance systemic corticosteroid use. This study showed that socioeconomic status was the strongest discriminator of race (C statistic of 0.75), followed by environment (0.65), demographics (0.64), smoking status (0.55), and co‐existing long‐term conditions (0.55) [5]. Global Evidence Linking Asthma with Multimorbidity and Treatable Traits The burden, patterns and adverse impact of multimorbidity in asthma and associated treatable traits have attracted much interest globally. In an observational study (2022–2024) involving the Singapore severe asthma registry, Tay et al. [48] reported ethnicity‐based disparities amongst 254 patients. As well as poor asthma clinical outcomes amongst Indian and Malay patients in comparison with Chinese patients, Indian and Malay patients had higher rates of high BMI and diabetes, whilst osteoporosis was significantly more common in Chinese patients. Bisquera et al. [64] conducted a retrospective cohort study (2005–2020) in an adult British population (n = 826,936) in the inner London borough in a primary care setting with a median follow up of 4.2 years. They included 32 long‐term conditions including asthma based on a consensus approach. 631,760 (76%) entered the study with no long‐term condition, 121,424 (15%) with 1 long‐term condition, 41,720 (5%) with 2 long‐term conditions, and 31,966 (4%) with three or more long‐term conditions. At the end of the study period, 24% developed ≥ 1, 5% had resolved long‐term condition, and 3% died. Deprivation, female sex, and Black ethnicity were independently associated with progress from single to two long‐term conditions and shorter period in a healthy state. However, asthma and multimorbidity was specifically not investigated in this study. Engelkes et al. [65] reported all‐cause mortality in patients (N = 586,436; severe asthma—7.3%) with asthma interrogating five European electronic databases from the Netherlands, Italy, UK, Denmark and Spain during the (2008–2013). Age and sex standardised all‐cause mortality rates were 5.2–9.5/1000 person‐years (PY) in asthma, and 11.3–14.8/1000 person‐years in severe asthma and all‐cause mortality rate in the first week following a severe asthma attack was 14.1–59.9/1000 person—years [65]. The main risk factors identified in this study were higher age, male gender, co‐existing long‐term conditions, smoking, and previous severe asthma attacks [65]. Co‐existing long‐term conditions significantly contributing were somewhat variable between countries. For example, in the UK cohort cancer, cerebrovascular disease, cardiovascular disease, obesity, diabetes and smoking status were significantly associated, although cardiovascular disease, obesity and smoking status were not significant in the Danish cohort [65]. Whilst this study provided important insights into asthma and multimorbidity, they were mainly related to the White population. Pattanaik et al. [66] analysed data from the Study on Global Ageing and Adult Health Wave‐2, involving 11,818 native Indian participants (N = 7118; age ≥ 50 years) for prevalence and patterns of multimorbidity relating to co‐occurrence of 8 long‐term conditions including arthritis, stroke, coronary artery disease, diabetes, chronic lung disease, asthma, depression, and hypertension. They found prevalence to be 45% with hypertension (22%) and arthritis (19%) as leading causes, with the former as the most frequent first onset condition. A number of disease dyads were detected with asthma pairing with hypertension. Park et al. investigated multimorbidity in Korean adults (N = 8370; ≥ 50 years) who participated in the Korean National Health and Nutrition Examination Survey (2013–2015) [67]. Ten chronic diseases were included in the study including hypertension, dyslipidaemia, stroke, osteoarthritis, tuberculosis, asthma, allergic rhinitis, depression, diabetes mellitus, and thyroid [67]. Latent class analysis revealed three clusters including ‘relatively healthy group’ (60%), ‘arthritis, asthma, allergic rhinitis, depression and thyroid disease’ group (11.8%) and the ‘cardiometabolic conditions group’ (27.8%). Deprivation was associated with the latter two groups with the ‘arthritis, asthma, allergic rhinitis, depression and thyroid disease’ group significantly associated with poorer quality of life [67]. In a recent UK study published as a conference abstract, Gassase et al. [68] investigated the association between the index of multiple deprivation and clinical outcomes in asthma including exacerbations, primary care consultations, emergency room visits, hospital and intensive care admissions and mortality amongst 787,621 patients and showed that deprivation was significantly associated with increased rates of healthcare utilisation in primary and secondary care, as well as significantly higher risk of asthma‐specific and all‐cause mortality. Janevic et al. [69] reported challenges faced by 25 African American women with asthma and multimorbidity (mean of 5.7 non‐T2 conditions), with at least one of three non‐T2 conditions including diabetes, heart disease or arthritis in a qualitative study. This study reported an adverse impact of asthma on non‐T2 conditions, as well as the impact of non‐T2 conditions on asthma. The main observations reported were that < 50% considered asthma as their main health problem (‘back seat’ to other conditions). Non‐T2 conditions such as pain‐related conditions and depression adversely impacted cognitive ability and motivation to self‐manage asthma [69]. Limitation of mobility due to chronic conditions and/or polypharmacy impacted directly or indirectly on asthma management [69]. Similarly, acute asthma attacks impacted on the management of other conditions, physical activity and were sometimes deemed to trigger other conditions [69]. In a systematic review including 6 observational studies in High Income countries in children 0–18 years, risk of intensive care admissions for asthma was associated with high salbutamol use, previous hospital admission, deprivation, allergies, Black ethnicity, pneumonia, rural residence, and multimorbidity [27]. The main co‐existing long‐term conditions were prematurity, congenital heart disease and chronic respiratory disorders [27]. Specifically, the authors identified a four‐fold higher risk and seven‐fold higher risk respectively of intensive care admission and mortality amongst Black children compared to White children and highlighted limitations in published evidence in terms of risk of bias and imprecision, and the need for further research to investigate risk factors contributing to intensive care admissions and fatal asthma in the paediatric age group. Whilst multimorbidity is challenging in Caucasian White patients with asthma, there are additional layers of complexities in patients from EMGs with respect to confounding variables related to deprivation, literacy, access to healthcare, confidence in health services, poor adherence with treatment, language barrier, and the need for a culturally targeted and tailored approach. Current single condition targeted service model puts patients at an enhanced risk of fragmented care, thus contributing to poor treatment adherence and engagement with clinical services, compounding healthcare inequities as patients are required to navigate complex and disjointed healthcare services. It could be argued that a single multidimensional asthma and multimorbidity clinic is likely to offer better continuity of care, trust, confidence, and better engagement with services and improve clinical outcomes. Treatable traits were defined as potentially modifiable factors which are (a) clinically relevant, (b) identifiable and measurable and (c) treatable. They were broadly categorised as pulmonary, extrapulmonary or behavioural/lifestyle. The treatable traits paradigm in airways disease was first proposed a decade ago as a framework for personalised patient care [70]. Strategies to address treatable traits would necessarily include multimodal approaches to deliver patient advice and support via a multidisciplinary team to manage common co‐existing T2 and non‐T2 conditions including sinonasal disease, gastro‐oesophageal reflux disease, breathing pattern disorder, weight management, osteoporosis, anxiety and depression as well as psychological/behavioural approaches to address contributory lifestyle risk factors such as non‐adherence, smoking or allergen exposure (which, in turn, benefit pulmonary and extrapulmonary factors). Subsequent studies have demonstrated the clinical efficacy of multimodal approaches to address treatable traits in difficult‐to‐treat/severe asthma. In a 16‐week randomised control trial of a nurse‐coordinated multimodal treatment process for Australian patients with difficult‐to‐treat asthma, McDonald et al. demonstrated significant improvements in asthma control and quality of life compared to standard care [71]. This study involved severe asthma patients with a mean ± standard deviation of about 10 ± 3 treatable traits per patient with a reasonable balance between pulmonary and extra pulmonary (4.85 ± 1.86) and behavioural (2.58 ± 1.31) traits. A retrospective analysis of a multidisciplinary approach to treatable traits in difficult‐to‐treat asthma by Lin et al. identified 5 distinct trait profiles (2 airway centric and 3 non‐airway centric) based on assessment for 12 treatable traits [72]. This study was conducted from 2014 to 2022 in a tertiary centre in Melbourne, Australia. It showed that 6 months of trait‐based tailored management was associated with significant improvement in asthma control, quality of life, lung function, exacerbations and oral corticosteroid use. A further study in the same centre by Denton et al. demonstrated that a systematic assessment of severe asthma patients and subsequent targeted management facilitated a 50% reduction in maintenance oral corticosteroid dose (independent of biologic co‐administration), alongside improved asthma symptom control and quality of life as well as exacerbation reduction in over 50% patients [73]. Furthermore, tailored self‐management programmes targeting extrapulmonary symptoms such as anxiety/depression have demonstrated potential to improve asthma quality of life as feasible and pragmatic complementary approaches to medical management [74]. These studies however, involved mainly White patients, and there is an urgent need for such studies amongst EMGs. Lessons can also be learnt from a French Pharmacoepidemiological nested case control study (Asthma E3N) [51]. This study was largely based in the Caucasian White French population, involving analysis of medications in a large cohort of 17,458 elderly women of whom 4328 had asthma [51]. Three multi‐medication profiles were delineated including few multimorbidity related medications, predominantly allergy related medications and predominantly metabolic multimorbidity related medications, with the latter two groups associated with poor asthma outcomes based on level of asthma therapy, asthma control, asthma exacerbations and asthma quality of life questionnaire [51]. These studies highlight a place for a multidimensional or an integrated holistic management of asthma with multimorbidity amongst EMGs employing a culturally tailored and targeted approach embedding education, primary prevention, secondary prevention, targeting treatable traits and offering basic management of common co‐existing T2 and non‐T2 long‐term conditions. Culturally tailored supportive interventions should address both surface or observable characteristics and deeper structures such as cultural, social, behavioural and environmental characteristics to facilitate better understanding and engagement with clinical services [75]. The main facilitators of self‐management reported in previous studies include culturally and socially adaptable education at a patient level [76]. Community‐based culturally tailored education has been successful in diabetes and cardiovascular disease [77, 78]. Lessons can be drawn from these studies to develop similar strategies for EMG patients with asthma and multimorbidity. In a cluster randomised control trial involving primary care practices in England and Scotland, Salisbury et al. [79] investigated the impact of 3D (dimensions of health, depression and drugs) interventional care on health‐related quality of life in patients with multimorbidity (≥ 3 long‐term conditions; N = 1546; 33 GP practices) and randomised practices to standard of care and 3D model with a 15 month follow up. The vast majority of participants in both groups were Caucasian White with ~3% EMGs or unknown ethnicity. Amongst 11 long‐term health conditions, the majority were cardiovascular or chronic kidney disease in both groups (> 93%–94%), followed by diabetes (52%–54%) and chronic obstructive pulmonary disease or asthma (49%–51%). No differences were detected between the two groups, although 3D care improved patient perceptions of quality of care and there was no specific additional resource utilisation. The authors made a case that provision of patient‐centred care that improves patient experience is one of three basic elements of healthcare [80]. Indeed, qualitative research exploring patient experiences in clinics across 7 European countries found that patients highlighted the need for co‐ordinated, multidisciplinary care that was personalised to their broad range of extra‐pulmonary symptoms [81]. A patient‐centred multimorbidity clinical service has been described in the Danish healthcare system, which involves an interface between primary care and specialist services [82]. This service includes a general physician, pharmacist and occupational therapist reviewing the patient in a single visit taking a holistic approach, formulating a detailed summary followed by a remote discussion with relevant specialists and feedback to patient and family physician [82]. Clinical outcomes and cost‐effectiveness were, however, not reported by the authors. Figures 2, 3, 4 illustrate possible interventions for asthma with multimorbidity amongst EMGs including a logic model. Asthma and multimorbidity holistic multidimensional management and likely impact. Illustration of holistic clinical management of common T2 and non T2 multimorbidity in asthma and potential impact of early interventions on clinical outcomes. Logic model summarising strategic approach to research. Logic model addressing current gaps in knowledge via development of multistranded research programme. A multi‐dimensional service model for asthma with multimorbidity amongst ethnic minority groups. A multidimensional culturally tailored service model for asthma and multimorbidity amongst ethnic minority groups. ACQ, Asthma control questionnaire; ACT, Asthma control test; BNP, B‐type natriuretic peptide; BP, Blood pressure; CXR, Chest X ray; ECG, Electrocardiogram; FeNO, Fractional exhaled nitric oxide; HCP, Healthcare professional; HR, Heart rate; PEFR, Peak expiratory flow rate. Gaps in Evidence in Asthma and Multimorbidity Amongst EMGs in High Income Countries The selection of T2 and non‐T2 multimorbidity in all published asthma and multimorbidity studies thus far has been based on investigator judgement and experience rather than an evidence‐based hierarchical prevalence estimate data in the local population. A number of areas warrant further research. First, a population‐based study employing a joined‐up interrogation of primary care and secondary care databases to determine the prevalence of asthma with T2 and non T2 multimorbidity amongst EMGs, delineating hierarchical occurrence in different age groups supplemented with a cluster analysis to describe patterns of associations and link to socio‐demographic variables and clinical outcomes might feed into shaping risk stratification strategies. Second, gaining deeper insight into views and perspectives of EMG patients and their carers regarding their lived experiences of receiving care for asthma and multimorbidity as per current standard of care might be helpful alongside experiences of healthcare professionals and healthcare managers in primary and secondary care involved in the delivery of asthma management amongst EMGs. Third, it is prudent to develop culturally tailored resources for patients and carers highlighting the importance of a holistic approach to asthma and multimorbidity and raising awareness regarding treatable traits, primary and secondary prevention measures, optimising pharmacotherapy with an aim to reduce polypharmacy might feed into improving clinical outcomes. Table 1 summarises some ‘proof of concept’ studies making a case for a multidimensional approach to clinical management of asthma and multimorbidity amongst EMGs and highlights the need for further research. TABLE 1Key ‘proof of concept’ studies in multimorbidity making a case for a multidimensional approach to clinical management and further research.Author (country)Study designKey findingsAnalysis and limitationPuri et al. (India) [83] 58,975 adults (≥ 45 years) from the Longitudinal Ageing Study in India, 2017–201816 noncommunicable diseases (NCDs) included:asthma, cancer, chronic bronchitis, chronic heart disease, chronic renal failure, chronic obstructive pulmonary disease, diabetes, gastrointestinal disorder, high cholesterol, hypertension, musculoskeletal disorder, neurological and psychiatric, skin disease, stroke, thyroid disease and urinary incontinence. Latent class analysis for common occurring patternsLogistic regression to investigate association between disease patterns with socioeconomic, demographic, lifestyle and anthropometric characteristics Top 5 conditions: Hypertension (26.9%), Gastrointestinal tract disorders (18.4%), m usculoskeletal disorders (16.2%), diabetes (11.7%) and skin diseases (5.2%) Hypertension was most frequent amongst disease combinations identified 6 patterns identified: ‘relatively healthy’hypertension’gastrointestinal disorders–hypertension–musculoskeletal disordersmusculoskeletal disorders–hypertension–asthma’,‘metabolic disorders’complex cardiometabolic disorders' Disease patterns were associated with socioeconomic, demographic, lifestyle and anthropometric NCDs based on self‐reportingNo causality was testedThis study was not specifically designed to study asthma and multimorbidity Chanoine et al. (France) [51] Analysis was N = 17,458 women participating in the Asthma‐E3N study Nested case–control study on asthma within the E3N study (2011–2012) General features and respiratory health, comprehensive outpatient dispensed medication database from 2004 onwards Cluster analysis identified asthma groups sharing similar medication profiles and association with adverse asthma events Network‐based analysis revealed more multi‐medications amongst women with asthma than those without 3 patterns/categories identified: Few multimorbidity‐related medications (43.5%)Predominantly allergic multimorbidity‐related medications (32.8%)Predominantly metabolic multimorbidity‐related medications (23.7%) Compared with women in category ‘a’, those belonging to ‘b’ & ‘c’ had an increased risk of adverse asthma events (uncontrolled asthma, acute asthma and asthma HRQoL) 50% of patients in category ‘c’ had mental health conditionsHolistic and continuity of care needed, where both physical and mental health conditions are managedHighlights the need to move away from a ‘one size fits all’ single disease guideline‐based approach to asthma management to a person‐based multimorbidity approachThis study involved mainly French White patients, so data is not generalisable, and specifically cannot be extrapolated to EMGs Domínguez‐Ortega et al. (Spain) [52] Prospective observational study Predictors of adverse events in patients who presented with ≥ 1 asthma adverse events in the previous year in the MEchanism of Genesis and Evolution of Asthma (MEGA) cohort N = 486; 23.7% mild, 35% moderate, 41.3% severe 15 co‐morbidities studied including food allergy, allergic rhinitis, chronic sinusitis and NSAID exacerbated respiratory disease Comorbidity detected in 56.4% (66.6% in severe asthma) Significant associations with adverse events: Bronchiectasis, chronic rhinosinusitis with nasal polyps, atopy, psychiatric illnesses, hyperlipidaemia, and hypertensionSputum eosinophil counts and TS inflammatory pattern Involved Spanish patients, so is not generalisable in other populations, and specifically cannot be extrapolated to EMGsMultimorbidity's included were based on physician selection rather than evidence based hierarchical prevalence estimates in asthma Pattanaik et al. (India) [66] WHO Study on Global AGEing and Adult Health (SAGE) Wave 2 (2014–2015) Part of a multi‐national study in Low‐ and Middle‐Income Countries Indian data analysed on participants ≥ 50 years (7118 [53% females] out of a total sample of 11,818) 24% belonged to most affluent quintile Hypertension was most frequent and was most frequent common first diagnosis Top 8 chronic conditions: Hypertension (22%)Arthritis (19%)Stroke (2.36%)Angina (3.27%)Diabetes (9.44%)Chronic lung disease (2%)Asthma (5.11%)Depression (2.3%) Dyads (7.7%) Triads (2.37%) Provides proof of concept regarding asthma as amongst top 8 chronic conditions amongst people ≥ 50 yearsNot generalisable to other age groupsDoes not provide insight regarding asthma and multimorbidity association Park et al. (Korea) [67] Participants ≥ 50 years (8370; mean age—62.5 years; 54% females) from the 6th Korean National Health and Nutrition Examination Survey (2013–2015) 10 chronic diseases included (hypertension, dyslipidaemia, stroke, osteoarthritis, tuberculosis, asthma, allergic rhinitis, depression, diabetes mellitus, and thyroid disease) Regression analysis to investigate associations between multimorbidity patterns, and sociodemographic factors and health‐related quality of life Top 6 chronic conditions: Hypertension (36%)Dyslipidaemia (22%)Osteoarthritis (20%)Diabetes mellitus (14%)Allergic rhinitis (8%) 3 patterns identified: Relatively healthy group (60.4%); number of co‐occurring diseases—mean (95% CI) 0.6 (0.6–0.6)Cardiometabolic conditions' group (27.8%); number of co‐occurring diseases—mean (95% CI) 2.6 (2.6–2.7)Arthritis, asthma, allergic rhinitis, depression, and thyroid disease’ group (11.8%); number of co‐occurring diseases—mean (95% CI) 2.9 (2.8–3.0) Risk factors: Female sex and lower socioeconomic group for categories b & c Poor health outcomes: Categories b & c Study was not specifically designed to investigate asthma and multimorbidityHowever, provides proof‐of‐concept regarding association of asthma with other common long‐term conditions amongst adults ≥ 50 years and intersection with poor deprivation and poor clinical outcomes Scelo et al. (International severe asthma registry) [45] Cross‐sectional study, 22 countries N = 11,821patients 30 co‐existing long‐term conditions studied: potentially T2‐related (69% at least 1 condition)potentially oral corticosteroid‐non‐T2 related multimorbidity (67% at least 1 condition)multimorbidity mimicking or aggravating asthma (55% at least 1 condition) 57% had ≥ 3 co‐morbiditiesNasal/sinus related conditions associated with significantly greater asthma exacerbationsOral corticosteroids related conditions had higher odds of long‐term corticosteroid usageMimicking/exacerbating conditions had higher odds of asthma exacerbationsGreater number of co‐existing conditions—worse clinical outcomes9/11 non‐T2 multimorbidity were associated with higher odds of long‐term oral corticosteroid usage Provides ‘proof‐of‐concept’ regarding importance of recognition of asthmatics with associated T2 and non‐T2 long‐term conditions due to an adverse impact on clinical outcomesData on ethnicity not provided/analysedMajority were High Income Countries from Europe and North AmericaHighlights a need for a holistic personalised clinical care for severe asthma as opposed to a single guideline standardised care for severe asthma Pate et al. (USA) [63] National Health Interview Survey data (2021) N = 7343 children and adolescents (2–17 years) and 29,329 adults (≥ 18 years) 8% ≥ 2 years—asthma and 52.3%—allergy symptomsAsthma‐T2 conditions prevalence higher amongst adult females compared to males and higher amongst boys compared to girlsAsthma‐T2 conditions higher in those from deprived background as per federal poverty level < 100 and non‐Hispanic Black peopleThis study did not identify enhanced risk of asthma attacks amongst children with asthma and co‐existing T2 conditionsAdults with asthma and T2 conditions had an enhanced risk of ≥ 1 asthma exacerbation in the preceding 12 months Survey data subjected to patient recallRelatively small sample size to conduct sub‐group analysisStudy conducted during the COVID‐19 pandemic, so may have had a potentially protective effect on asthma exacerbation due to lower infection rate and low levels of air pollutionProvides evidence regarding disparities in asthma and T2 conditions based on age, sex, ethnicity and deprivationWomen, deprivation and non‐Hispanic Black ethnicity more likely to report asthma with T2‐condition/s Patel et al. (USA) [84] Cross‐sectional interview data from the National Health Interview Survey N = 66,790; period; 2007–2012; Age 0 to 17 years; EMGs included5% of children had 1 or more co‐existing health condition (multimorbidity) and 9 co‐existing conditions were investigated including congenital heart disease, autism, muscular dystrophy, sickle cell, hypertension, diabetes, other heart condition, arthritis and cerebral palsy Patients with asthma were 1.6 times more likely to manage co‐existing long‐term conditions compared to those without asthmaThe cumulative number of co‐existing long‐term conditions were associated with adverse outcomes from asthma including acute attacks, school absenteeism and hospital admissions Provides proof of concept regarding higher prevalence of multimorbidity in children and young adults with asthmaSubgroup analysis on EMGs were not reportedSelection bias regarding co‐existing long‐term conditionsT2 conditions were not investigatedSurvey data subject to reporting and health seeking behaviourBMI data not available Simms‐Willams et al. (UK) [6] Cohort study using linked primary care (Clinical Practice Research Datalink Aurum) and secondary care (Hospital Episode Statistics Admitted Patient Care) dataIncluded ≥ 5 years with asthma N = 90,989 children aged 5–11 years; N = 114,927 adolescents aged 12–17 years and N = 1179 410 adults ≥ 18 years; period: 2017–2019Outcomes: Primary—asthma‐related hospital admission; secondary—asthma‐related intensive care unit admissionAdjusted incident rate ratios determined Risk for asthma‐related hospital admissions: younger age, female, deprivation, EMGsAdults: smoking, obesity, atopic conditions, gastro‐oesophageal reflux disease, anxiety and depression Limited number of non‐T2 long‐term conditions were includedAsthma may be misdiagnosed in primary carePotential misclassification of asthma‐related hospital admission resulting in overestimationPotential under diagnosis of anxiety and depressionInteraction between risk factors were not studiedEmergency room admissions were not included in the dataset which result in underestimation of adverse clinical outcomes Lin et al. (UK) [85] Prospective cohort study (2006–2010) based on the UK Biobank linked to primary care records, hospital admission and death register data N = 51,335 with asthma and N = 395,890 without asthmaMedian follow up: 13.8 yearsCox proportional hazards models and multi‐state modelsFollowed up development of cardio‐metabolic disorders (CMD; type 2 diabetes, coronary heart disease, and stroke) and cardio‐metabolic multimorbidity (CMM) 60,033 participants (13.4%) developed CMD, of whom 7048 (1.6%) progressed to CMMAsthma was associated with enhanced risk of all the 3 CMDs and CMM (hazard ratio = 1.54, 95% CI 1.44–1.64)Effect greater in women This study serves as a proof of concept for ‘holistic care’ in the context of asthma and multimorbidityHighlights potential benefit for strategies for early diagnosis, primary and secondary prevention of CMDs including addressing treatable traits relevant to CMDs Verest et al. (The Netherlands) [86] Healthy Life in an Urban Setting study (HELIUS); 2011–2015Random sampling and questionnaire based N = 23,942; Dutch (N = 4582), South‐Asian Surinamese (N = 3258), African Surinamese (N = 4267), Ghanaian (N = 2282), Turkish (N = 3879) and Moroccan (N = 4094)Aged 18–70 yearsList of 20 conditions included as reported by participants in the preceding 12 months After adjustment of socioeconomic status, adjusted odds ratio for multimorbidity significantly higher amongst EMGsHigher prevalence of multimorbidity amongst both men and women from EMGsEarlier onset multimorbidity by 1–3 decades amongst EMGs Asthma and multimorbidity not specifically studiedData showed an enhanced risk of multimorbidity amongst Dutch EMGsData limited by self‐reportingHigher age limit set at 70 years, so not inclusive of the elderly who are likely to have a greater burden of multimorbidity George et al. (USA) [87] N = 402,403; ≥ 12 years; moderate‐to‐severe asthmaData extracted from electronic health records2012–2018; risk factors for uncontrolled asthma determined as per Cox proportional hazard modelEthnicity: African‐American 13.5%; Asian 1.5%; White 78.9%; Other/unknown 6.1%Good geographical cover of USA including Midwest 53.2%, Northeast 12%, South 23.9%, West 7.3%, Other/unknown 3.6% Hazard ratios: African American—2.08Hispanic—1.34Medicaid insurance—1.71Age 12 to < 18 years—1.20BMI ≥ 35 kg/m2–1.20Female sex—1.19Blood eosinophils ≥ 300/μL—1.40Food allergy—1.31Pneumonia—1.3 Asthma severity defined as per medication use in the last 12 monthsData provides evidence of intersection between poor clinical outcome and ethnicity, co‐existing long‐term condition/s as well as other co‐variatesSocio‐economic status was not included in analysis> 90% participants were Caucasian White; sub‐analysis for EMGs not presented Arias et al. (USA) [88] Secondary analysis (2008–2013) of National Survey on Drug Use and Health N = 206,993 adultsInvestigated association between asthma and mental health (past year serious psychological distress [SPD] and doctor diagnosis of depression)Bivariate Chi‐square and multivariable regression Current and lifetime asthma was significantly associated with past year SPD and depression amongst non‐Hispanic White, Hispanics and African‐American people Cross‐sectional study and does not provide evidence for causalityAsians not included in this studySelf‐reported data has limitations and subject to underestimates Key ‘proof of concept’ studies in multimorbidity making a case for a multidimensional approach to clinical management and further research. 58,975 adults (≥ 45 years) from the Longitudinal Ageing Study in India, 2017–2018 58,975 adults (≥ 45 years) from the Longitudinal Ageing Study in India, 2017–2018 16 noncommunicable diseases (NCDs) included: 16 noncommunicable diseases (NCDs) included: Latent class analysis for common occurring patterns Latent class analysis for common occurring patterns Logistic regression to investigate association between disease patterns with socioeconomic, demographic, lifestyle and anthropometric characteristics Logistic regression to investigate association between disease patterns with socioeconomic, demographic, lifestyle and anthropometric characteristics Top 5 conditions: Hypertension (26.9%), Gastrointestinal tract disorders (18.4%), m usculoskeletal disorders (16.2%), diabetes (11.7%) and skin diseases (5.2%) Hypertension was most frequent amongst disease combinations identified 6 patterns identified: ‘relatively healthy’hypertension’gastrointestinal disorders–hypertension–musculoskeletal disordersmusculoskeletal disorders–hypertension–asthma’,‘metabolic disorders’complex cardiometabolic disorders' ‘relatively healthy’ ‘relatively healthy’ hypertension’ hypertension’ gastrointestinal disorders–hypertension–musculoskeletal disorders gastrointestinal disorders–hypertension–musculoskeletal disorders musculoskeletal disorders–hypertension–asthma’, musculoskeletal disorders–hypertension–asthma’, ‘metabolic disorders’ ‘metabolic disorders’ complex cardiometabolic disorders' complex cardiometabolic disorders' Disease patterns were associated with socioeconomic, demographic, lifestyle and anthropometric NCDs based on self‐reporting NCDs based on self‐reporting No causality was tested No causality was tested This study was not specifically designed to study asthma and multimorbidity This study was not specifically designed to study asthma and multimorbidity Analysis was N = 17,458 women participating in the Asthma‐E3N study Nested case–control study on asthma within the E3N study (2011–2012) General features and respiratory health, comprehensive outpatient dispensed medication database from 2004 onwards Cluster analysis identified asthma groups sharing similar medication profiles and association with adverse asthma events Network‐based analysis revealed more multi‐medications amongst women with asthma than those without 3 patterns/categories identified: Few multimorbidity‐related medications (43.5%)Predominantly allergic multimorbidity‐related medications (32.8%)Predominantly metabolic multimorbidity‐related medications (23.7%) Few multimorbidity‐related medications (43.5%) Few multimorbidity‐related medications (43.5%) Predominantly allergic multimorbidity‐related medications (32.8%) Predominantly allergic multimorbidity‐related medications (32.8%) Predominantly metabolic multimorbidity‐related medications (23.7%) Predominantly metabolic multimorbidity‐related medications (23.7%) Compared with women in category ‘a’, those belonging to ‘b’ & ‘c’ had an increased risk of adverse asthma events (uncontrolled asthma, acute asthma and asthma HRQoL) 50% of patients in category ‘c’ had mental health conditions 50% of patients in category ‘c’ had mental health conditions Holistic and continuity of care needed, where both physical and mental health conditions are managed Holistic and continuity of care needed, where both physical and mental health conditions are managed Highlights the need to move away from a ‘one size fits all’ single disease guideline‐based approach to asthma management to a person‐based multimorbidity approach Highlights the need to move away from a ‘one size fits all’ single disease guideline‐based approach to asthma management to a person‐based multimorbidity approach This study involved mainly French White patients, so data is not generalisable, and specifically cannot be extrapolated to EMGs This study involved mainly French White patients, so data is not generalisable, and specifically cannot be extrapolated to EMGs Prospective observational study Predictors of adverse events in patients who presented with ≥ 1 asthma adverse events in the previous year in the MEchanism of Genesis and Evolution of Asthma (MEGA) cohort N = 486; 23.7% mild, 35% moderate, 41.3% severe 15 co‐morbidities studied including food allergy, allergic rhinitis, chronic sinusitis and NSAID exacerbated respiratory disease Comorbidity detected in 56.4% (66.6% in severe asthma) Significant associations with adverse events: Bronchiectasis, chronic rhinosinusitis with nasal polyps, atopy, psychiatric illnesses, hyperlipidaemia, and hypertensionSputum eosinophil counts and TS inflammatory pattern Bronchiectasis, chronic rhinosinusitis with nasal polyps, atopy, psychiatric illnesses, hyperlipidaemia, and hypertension Bronchiectasis, chronic rhinosinusitis with nasal polyps, atopy, psychiatric illnesses, hyperlipidaemia, and hypertension Sputum eosinophil counts and TS inflammatory pattern Sputum eosinophil counts and TS inflammatory pattern Involved Spanish patients, so is not generalisable in other populations, and specifically cannot be extrapolated to EMGs Involved Spanish patients, so is not generalisable in other populations, and specifically cannot be extrapolated to EMGs Multimorbidity's included were based on physician selection rather than evidence based hierarchical prevalence estimates in asthma Multimorbidity's included were based on physician selection rather than evidence based hierarchical prevalence estimates in asthma WHO Study on Global AGEing and Adult Health (SAGE) Wave 2 (2014–2015) Part of a multi‐national study in Low‐ and Middle‐Income Countries Indian data analysed on participants ≥ 50 years (7118 [53% females] out of a total sample of 11,818) 24% belonged to most affluent quintile Hypertension was most frequent and was most frequent common first diagnosis Top 8 chronic conditions: Hypertension (22%)Arthritis (19%)Stroke (2.36%)Angina (3.27%)Diabetes (9.44%)Chronic lung disease (2%)Asthma (5.11%)Depression (2.3%) Hypertension (22%) Hypertension (22%) Arthritis (19%) Arthritis (19%) Stroke (2.36%) Stroke (2.36%) Angina (3.27%) Angina (3.27%) Diabetes (9.44%) Diabetes (9.44%) Chronic lung disease (2%) Chronic lung disease (2%) Asthma (5.11%) Asthma (5.11%) Depression (2.3%) Depression (2.3%) Dyads (7.7%) Triads (2.37%) Provides proof of concept regarding asthma as amongst top 8 chronic conditions amongst people ≥ 50 years Provides proof of concept regarding asthma as amongst top 8 chronic conditions amongst people ≥ 50 years Not generalisable to other age groups Not generalisable to other age groups Does not provide insight regarding asthma and multimorbidity association Does not provide insight regarding asthma and multimorbidity association Participants ≥ 50 years (8370; mean age—62.5 years; 54% females) from the 6th Korean National Health and Nutrition Examination Survey (2013–2015) 10 chronic diseases included (hypertension, dyslipidaemia, stroke, osteoarthritis, tuberculosis, asthma, allergic rhinitis, depression, diabetes mellitus, and thyroid disease) Regression analysis to investigate associations between multimorbidity patterns, and sociodemographic factors and health‐related quality of life Top 6 chronic conditions: Hypertension (36%)Dyslipidaemia (22%)Osteoarthritis (20%)Diabetes mellitus (14%)Allergic rhinitis (8%) Hypertension (36%) Hypertension (36%) Dyslipidaemia (22%) Dyslipidaemia (22%) Osteoarthritis (20%) Osteoarthritis (20%) Diabetes mellitus (14%) Diabetes mellitus (14%) Allergic rhinitis (8%) Allergic rhinitis (8%) 3 patterns identified: Relatively healthy group (60.4%); number of co‐occurring diseases—mean (95% CI) 0.6 (0.6–0.6)Cardiometabolic conditions' group (27.8%); number of co‐occurring diseases—mean (95% CI) 2.6 (2.6–2.7)Arthritis, asthma, allergic rhinitis, depression, and thyroid disease’ group (11.8%); number of co‐occurring diseases—mean (95% CI) 2.9 (2.8–3.0) Relatively healthy group (60.4%); number of co‐occurring diseases—mean (95% CI) 0.6 (0.6–0.6) Relatively healthy group (60.4%); number of co‐occurring diseases—mean (95% CI) 0.6 (0.6–0.6) Cardiometabolic conditions' group (27.8%); number of co‐occurring diseases—mean (95% CI) 2.6 (2.6–2.7) Cardiometabolic conditions' group (27.8%); number of co‐occurring diseases—mean (95% CI) 2.6 (2.6–2.7) Arthritis, asthma, allergic rhinitis, depression, and thyroid disease’ group (11.8%); number of co‐occurring diseases—mean (95% CI) 2.9 (2.8–3.0) Arthritis, asthma, allergic rhinitis, depression, and thyroid disease’ group (11.8%); number of co‐occurring diseases—mean (95% CI) 2.9 (2.8–3.0) Risk factors: Female sex and lower socioeconomic group for categories b & c Poor health outcomes: Categories b & c Study was not specifically designed to investigate asthma and multimorbidity Study was not specifically designed to investigate asthma and multimorbidity However, provides proof‐of‐concept regarding association of asthma with other common long‐term conditions amongst adults ≥ 50 years and intersection with poor deprivation and poor clinical outcomes However, provides proof‐of‐concept regarding association of asthma with other common long‐term conditions amongst adults ≥ 50 years and intersection with poor deprivation and poor clinical outcomes Cross‐sectional study, 22 countries N = 11,821patients 30 co‐existing long‐term conditions studied: potentially T2‐related (69% at least 1 condition)potentially oral corticosteroid‐non‐T2 related multimorbidity (67% at least 1 condition)multimorbidity mimicking or aggravating asthma (55% at least 1 condition) potentially T2‐related (69% at least 1 condition) potentially T2‐related (69% at least 1 condition) potentially oral corticosteroid‐non‐T2 related multimorbidity (67% at least 1 condition) potentially oral corticosteroid‐non‐T2 related multimorbidity (67% at least 1 condition) multimorbidity mimicking or aggravating asthma (55% at least 1 condition) multimorbidity mimicking or aggravating asthma (55% at least 1 condition) 57% had ≥ 3 co‐morbidities 57% had ≥ 3 co‐morbidities Nasal/sinus related conditions associated with significantly greater asthma exacerbations Nasal/sinus related conditions associated with significantly greater asthma exacerbations Oral corticosteroids related conditions had higher odds of long‐term corticosteroid usage Oral corticosteroids related conditions had higher odds of long‐term corticosteroid usage Mimicking/exacerbating conditions had higher odds of asthma exacerbations Mimicking/exacerbating conditions had higher odds of asthma exacerbations Greater number of co‐existing conditions—worse clinical outcomes Greater number of co‐existing conditions—worse clinical outcomes 9/11 non‐T2 multimorbidity were associated with higher odds of long‐term oral corticosteroid usage 9/11 non‐T2 multimorbidity were associated with higher odds of long‐term oral corticosteroid usage Provides ‘proof‐of‐concept’ regarding importance of recognition of asthmatics with associated T2 and non‐T2 long‐term conditions due to an adverse impact on clinical outcomes Provides ‘proof‐of‐concept’ regarding importance of recognition of asthmatics with associated T2 and non‐T2 long‐term conditions due to an adverse impact on clinical outcomes Data on ethnicity not provided/analysed Data on ethnicity not provided/analysed Majority were High Income Countries from Europe and North America Majority were High Income Countries from Europe and North America Highlights a need for a holistic personalised clinical care for severe asthma as opposed to a single guideline standardised care for severe asthma Highlights a need for a holistic personalised clinical care for severe asthma as opposed to a single guideline standardised care for severe asthma National Health Interview Survey data (2021) N = 7343 children and adolescents (2–17 years) and 29,329 adults (≥ 18 years) 8% ≥ 2 years—asthma and 52.3%—allergy symptoms 8% ≥ 2 years—asthma and 52.3%—allergy symptoms Asthma‐T2 conditions prevalence higher amongst adult females compared to males and higher amongst boys compared to girls Asthma‐T2 conditions prevalence higher amongst adult females compared to males and higher amongst boys compared to girls Asthma‐T2 conditions higher in those from deprived background as per federal poverty level < 100 and non‐Hispanic Black people Asthma‐T2 conditions higher in those from deprived background as per federal poverty level < 100 and non‐Hispanic Black people This study did not identify enhanced risk of asthma attacks amongst children with asthma and co‐existing T2 conditions This study did not identify enhanced risk of asthma attacks amongst children with asthma and co‐existing T2 conditions Adults with asthma and T2 conditions had an enhanced risk of ≥ 1 asthma exacerbation in the preceding 12 months Adults with asthma and T2 conditions had an enhanced risk of ≥ 1 asthma exacerbation in the preceding 12 months Survey data subjected to patient recall Survey data subjected to patient recall Relatively small sample size to conduct sub‐group analysis Relatively small sample size to conduct sub‐group analysis Study conducted during the COVID‐19 pandemic, so may have had a potentially protective effect on asthma exacerbation due to lower infection rate and low levels of air pollution Study conducted during the COVID‐19 pandemic, so may have had a potentially protective effect on asthma exacerbation due to lower infection rate and low levels of air pollution Provides evidence regarding disparities in asthma and T2 conditions based on age, sex, ethnicity and deprivation Provides evidence regarding disparities in asthma and T2 conditions based on age, sex, ethnicity and deprivation Women, deprivation and non‐Hispanic Black ethnicity more likely to report asthma with T2‐condition/s Women, deprivation and non‐Hispanic Black ethnicity more likely to report asthma with T2‐condition/s Cross‐sectional interview data from the National Health Interview Survey Cross‐sectional interview data from the National Health Interview Survey N = 66,790; period; 2007–2012; Age 0 to 17 years; EMGs included N = 66,790; period; 2007–2012; Age 0 to 17 years; EMGs included 5% of children had 1 or more co‐existing health condition (multimorbidity) and 9 co‐existing conditions were investigated including congenital heart disease, autism, muscular dystrophy, sickle cell, hypertension, diabetes, other heart condition, arthritis and cerebral palsy 5% of children had 1 or more co‐existing health condition (multimorbidity) and 9 co‐existing conditions were investigated including congenital heart disease, autism, muscular dystrophy, sickle cell, hypertension, diabetes, other heart condition, arthritis and cerebral palsy Patients with asthma were 1.6 times more likely to manage co‐existing long‐term conditions compared to those without asthma Patients with asthma were 1.6 times more likely to manage co‐existing long‐term conditions compared to those without asthma The cumulative number of co‐existing long‐term conditions were associated with adverse outcomes from asthma including acute attacks, school absenteeism and hospital admissions The cumulative number of co‐existing long‐term conditions were associated with adverse outcomes from asthma including acute attacks, school absenteeism and hospital admissions Provides proof of concept regarding higher prevalence of multimorbidity in children and young adults with asthma Provides proof of concept regarding higher prevalence of multimorbidity in children and young adults with asthma Subgroup analysis on EMGs were not reported Subgroup analysis on EMGs were not reported Selection bias regarding co‐existing long‐term conditions Selection bias regarding co‐existing long‐term conditions T2 conditions were not investigated T2 conditions were not investigated Survey data subject to reporting and health seeking behaviour Survey data subject to reporting and health seeking behaviour BMI data not available BMI data not available Cohort study using linked primary care (Clinical Practice Research Datalink Aurum) and secondary care (Hospital Episode Statistics Admitted Patient Care) data Cohort study using linked primary care (Clinical Practice Research Datalink Aurum) and secondary care (Hospital Episode Statistics Admitted Patient Care) data Included ≥ 5 years with asthma Included ≥ 5 years with asthma N = 90,989 children aged 5–11 years; N = 114,927 adolescents aged 12–17 years and N = 1179 410 adults ≥ 18 years; period: 2017–2019 N = 90,989 children aged 5–11 years; N = 114,927 adolescents aged 12–17 years and N = 1179 410 adults ≥ 18 years; period: 2017–2019 Outcomes: Primary—asthma‐related hospital admission; secondary—asthma‐related intensive care unit admission Outcomes: Primary—asthma‐related hospital admission; secondary—asthma‐related intensive care unit admission Adjusted incident rate ratios determined Adjusted incident rate ratios determined Risk for asthma‐related hospital admissions: younger age, female, deprivation, EMGs Risk for asthma‐related hospital admissions: younger age, female, deprivation, EMGs Adults: smoking, obesity, atopic conditions, gastro‐oesophageal reflux disease, anxiety and depression Adults: smoking, obesity, atopic conditions, gastro‐oesophageal reflux disease, anxiety and depression Limited number of non‐T2 long‐term conditions were included Limited number of non‐T2 long‐term conditions were included Asthma may be misdiagnosed in primary care Asthma may be misdiagnosed in primary care Potential misclassification of asthma‐related hospital admission resulting in overestimation Potential misclassification of asthma‐related hospital admission resulting in overestimation Potential under diagnosis of anxiety and depression Potential under diagnosis of anxiety and depression Interaction between risk factors were not studied Interaction between risk factors were not studied Emergency room admissions were not included in the dataset which result in underestimation of adverse clinical outcomes Emergency room admissions were not included in the dataset which result in underestimation of adverse clinical outcomes Prospective cohort study (2006–2010) based on the UK Biobank linked to primary care records, hospital admission and death register data Prospective cohort study (2006–2010) based on the UK Biobank linked to primary care records, hospital admission and death register data N = 51,335 with asthma and N = 395,890 without asthma N = 51,335 with asthma and N = 395,890 without asthma Median follow up: 13.8 years Median follow up: 13.8 years Cox proportional hazards models and multi‐state models Cox proportional hazards models and multi‐state models Followed up development of cardio‐metabolic disorders (CMD; type 2 diabetes, coronary heart disease, and stroke) and cardio‐metabolic multimorbidity (CMM) Followed up development of cardio‐metabolic disorders (CMD; type 2 diabetes, coronary heart disease, and stroke) and cardio‐metabolic multimorbidity (CMM) 60,033 participants (13.4%) developed CMD, of whom 7048 (1.6%) progressed to CMM 60,033 participants (13.4%) developed CMD, of whom 7048 (1.6%) progressed to CMM Asthma was associated with enhanced risk of all the 3 CMDs and CMM (hazard ratio = 1.54, 95% CI 1.44–1.64) Asthma was associated with enhanced risk of all the 3 CMDs and CMM (hazard ratio = 1.54, 95% CI 1.44–1.64) Effect greater in women Effect greater in women This study serves as a proof of concept for ‘holistic care’ in the context of asthma and multimorbidity This study serves as a proof of concept for ‘holistic care’ in the context of asthma and multimorbidity Highlights potential benefit for strategies for early diagnosis, primary and secondary prevention of CMDs including addressing treatable traits relevant to CMDs Highlights potential benefit for strategies for early diagnosis, primary and secondary prevention of CMDs including addressing treatable traits relevant to CMDs Healthy Life in an Urban Setting study (HELIUS); 2011–2015 Healthy Life in an Urban Setting study (HELIUS); 2011–2015 Random sampling and questionnaire based Random sampling and questionnaire based N = 23,942; Dutch (N = 4582), South‐Asian Surinamese (N = 3258), African Surinamese (N = 4267), Ghanaian (N = 2282), Turkish (N = 3879) and Moroccan (N = 4094) N = 23,942; Dutch (N = 4582), South‐Asian Surinamese (N = 3258), African Surinamese (N = 4267), Ghanaian (N = 2282), Turkish (N = 3879) and Moroccan (N = 4094) Aged 18–70 years Aged 18–70 years List of 20 conditions included as reported by participants in the preceding 12 months List of 20 conditions included as reported by participants in the preceding 12 months After adjustment of socioeconomic status, adjusted odds ratio for multimorbidity significantly higher amongst EMGs After adjustment of socioeconomic status, adjusted odds ratio for multimorbidity significantly higher amongst EMGs Higher prevalence of multimorbidity amongst both men and women from EMGs Higher prevalence of multimorbidity amongst both men and women from EMGs Earlier onset multimorbidity by 1–3 decades amongst EMGs Earlier onset multimorbidity by 1–3 decades amongst EMGs Asthma and multimorbidity not specifically studied Asthma and multimorbidity not specifically studied Data showed an enhanced risk of multimorbidity amongst Dutch EMGs Data showed an enhanced risk of multimorbidity amongst Dutch EMGs Data limited by self‐reporting Data limited by self‐reporting Higher age limit set at 70 years, so not inclusive of the elderly who are likely to have a greater burden of multimorbidity Higher age limit set at 70 years, so not inclusive of the elderly who are likely to have a greater burden of multimorbidity N = 402,403; ≥ 12 years; moderate‐to‐severe asthma N = 402,403; ≥ 12 years; moderate‐to‐severe asthma Data extracted from electronic health records Data extracted from electronic health records 2012–2018; risk factors for uncontrolled asthma determined as per Cox proportional hazard model 2012–2018; risk factors for uncontrolled asthma determined as per Cox proportional hazard model Ethnicity: African‐American 13.5%; Asian 1.5%; White 78.9%; Other/unknown 6.1% Ethnicity: African‐American 13.5%; Asian 1.5%; White 78.9%; Other/unknown 6.1% Good geographical cover of USA including Midwest 53.2%, Northeast 12%, South 23.9%, West 7.3%, Other/unknown 3.6% Good geographical cover of USA including Midwest 53.2%, Northeast 12%, South 23.9%, West 7.3%, Other/unknown 3.6% African American—2.08 African American—2.08 Hispanic—1.34 Hispanic—1.34 Medicaid insurance—1.71 Medicaid insurance—1.71 Age 12 to < 18 years—1.20 Age 12 to < 18 years—1.20 BMI ≥ 35 kg/m2–1.20 BMI ≥ 35 kg/m2–1.20 Female sex—1.19 Female sex—1.19 Blood eosinophils ≥ 300/μL—1.40 Blood eosinophils ≥ 300/μL—1.40 Food allergy—1.31 Food allergy—1.31 Pneumonia—1.3 Pneumonia—1.3 Asthma severity defined as per medication use in the last 12 months Asthma severity defined as per medication use in the last 12 months Data provides evidence of intersection between poor clinical outcome and ethnicity, co‐existing long‐term condition/s as well as other co‐variates Data provides evidence of intersection between poor clinical outcome and ethnicity, co‐existing long‐term condition/s as well as other co‐variates Socio‐economic status was not included in analysis Socio‐economic status was not included in analysis > 90% participants were Caucasian White; sub‐analysis for EMGs not presented > 90% participants were Caucasian White; sub‐analysis for EMGs not presented Secondary analysis (2008–2013) of National Survey on Drug Use and Health Secondary analysis (2008–2013) of National Survey on Drug Use and Health N = 206,993 adults N = 206,993 adults Investigated association between asthma and mental health (past year serious psychological distress [SPD] and doctor diagnosis of depression) Investigated association between asthma and mental health (past year serious psychological distress [SPD] and doctor diagnosis of depression) Bivariate Chi‐square and multivariable regression Bivariate Chi‐square and multivariable regression Current and lifetime asthma was significantly associated with past year SPD and depression amongst non‐Hispanic White, Hispanics and African‐American people Current and lifetime asthma was significantly associated with past year SPD and depression amongst non‐Hispanic White, Hispanics and African‐American people Cross‐sectional study and does not provide evidence for causality Cross‐sectional study and does not provide evidence for causality Asians not included in this study Asians not included in this study Self‐reported data has limitations and subject to underestimates Self‐reported data has limitations and subject to underestimates Conclusion Asthma places a significant burden at both individual and societal levels. It frequently occurs alongside multiple long‐term health conditions within a framework of multimorbidity. Emerging evidence shows that greater multimorbidity burden is associated with worse asthma outcomes whilst addressing treatable traits and co‐existing T2 and non‐T2 long‐term conditions can improve asthma outcomes. People from EMGs often from a deprived socioeconomic background, experience an increased health disadvantage and detrimental impacts from multimorbidity There is now a clear imperative need to better understand the nature and impacts of asthma with multimorbidity in EMGs and use that new knowledge to design bespoke and holistic clinical care pathways and address health inequalities and improve the health status, and long‐term prognosis. This requires a multipronged joined up and an integrated approach involving patients, patient organisations, policy makers and healthcare providers. This includes the development of novel culturally tailored multidisciplinary approaches to support the bespoke needs of EMGs with asthma, improve access to healthcare for marginalised and deprived hard to reach people in the community, strategies to improve health literacy, upskill healthcare professionals in cultural awareness and facilitate diverse leadership at all levels in health services with an aim to drive new and equitable initiatives to eliminate institutional racism where it exists. Author Contributions All authors contributed to conceptualisation. M.T.K. led the write up in collaboration with S.M., B.A., A.F., R.K.n., R.K.u.r., and A.H.M. All authors edited and approved the final version of the manuscript. Conflicts of Interest M.T.K. received research grants from NIHR, FSA, MRC CiC and GCRF. He is clinical lead for Equality, Diversity and Inclusion for College of Medicine and Health, University of Birmingham. A.H.M. declares no conflicts of interest in relation to this work. He otherwise received personal and institutional payments for talks, advisory board meetings, sponsorships to attend conferences from AZ, GSK, Sanofi and Chiesi, and received a research grant from NIHR. Other co‐authors have no conflicts of interest to declare.